The Indian Pharmaceutical Market (IPM) continued its strong growth trajectory in May 2026, registering 10.9 per cent value growth and 1.4 per cent volume growth over the corresponding period last year. The market generated monthly sales of Rs 21,805 crore, with several major therapy segments reporting robust gains in both value and volume terms, according to latest report from Pharmarack Technologies.
Among the largest therapy groups, Cardiac continued to dominate the market with sales of Rs 3,184 crore, accounting for 15 per cent of IPM sales during the month. The segment recorded 13.9 per cent value growth and 2.9 per cent volume growth, reinforcing its position as the largest contributor to the pharmaceutical market. Gastro Intestinal, the second-largest therapy segment with sales of Rs 2,680 crore, posted 6.7 per cent value growth, although volumes remained largely flat with a marginal 0.1 per cent decline. Anti-Infectives, which contributed 10 per cent of the market and generated sales of Rs 2,221 crore, reported 6.1 per cent value growth, while volumes declined 4.0 per cent, indicating continued pressure on prescription demand in the segment.
Among the fastest-growing major therapies, Anti-Diabetic therapies recorded monthly sales of Rs 2,151 crore and delivered 16.8 per cent value growth along with 1.3 per cent volume growth, reflecting sustained demand for diabetes management products. Respiratory therapies also reported a strong performance, posting 12.3 per cent value growth and an impressive 10.0 per cent volume growth on sales of Rs 1,411 crore, making it one of the strongest volume-driven growth segments in the market. The Vitamin, Mineral and Nutrition segment generated sales of Rs 2,024 crore, recording 12.5 per cent value growth and 5.9 per cent volume growth, while Neuro/CNS therapies posted 11.0 per cent value growth and 1.1 per cent volume growth on sales of Rs 1,488 crore.
Several smaller therapy groups outperformed the broader market. Vaccines emerged as the fastest-growing therapy segment, recording 17.6 per cent value growth and 15.5 per cent volume growth on sales of Rs 223 crore. Urology therapies delivered 15.1 per cent value growth and 6.8 per cent volume growth, while Anti-Neoplastics reported 13.4 per cent value growth and 7.6 per cent volume growth, reflecting continued momentum in specialty therapies. Others, a diversified category, recorded 16.1 per cent value growth and 12.5 per cent volume growth, while the Sex Stimulants/Rejuvenators segment reported 14.2 per cent value growth and 7.0 per cent volume growth.
On the other hand, a few therapy groups faced volume pressure despite positive value growth. Pain/Analgesics reported 8.4 per cent value growth but volumes declined 1.7 per cent. Blood Related therapies grew 11.0 per cent in value, although volumes remained marginally negative at 0.2 per cent. Ophthal/Otologicals recorded 5.2 per cent value growth but witnessed a 5.7 per cent decline in volumes, while Hormones posted 3.4 per cent value growth and a 6.9 per cent decline in volume growth. The weakest-performing therapy segment during the month was Anti-Malarials, which reported a 4.5 per cent decline in value growth and a 3.7 per cent decline in volume growth, with sales of Rs 47 crore.
Commenting on the market performance, Sheetal Sapale, Vice President – Commercial at Pharmarack Technologies, said "The Indian Pharmaceutical Market maintained its healthy growth momentum in May 2026, supported by strong performances across several key therapy areas. Cardiac, Anti-Diabetic and Respiratory therapies continued to drive market expansion, while Vaccines, Urology and Anti-Neoplastics delivered some of the strongest growth rates. The broad-based value growth across most therapy segments highlights the resilience of pharmaceutical demand and the continued expansion of chronic and specialty care therapies in India."
Key Therapy Highlights – May 2026
Narayan Kulkarni